Japan Patient Support Programs (PSP) Market Analysis Sample Report

A sample report on Japan Patient Support Programs (PSP) Market Analysis Includes Market Size, Market Segmented by Types and Key Competitors (Data forecasts from 2022 – 2030F) www.insights10.com

This report presents a strategic analysis of the Japan Patient Support Programs (PSP) Market and a forecast for its development in the medium and long term. It provides a comprehensive overview of the market value, dynamics, segmentation, types of clinical diagnostics, point- of-care testing, main players, growth and demand drivers, challenges & future outlook, etc. This is one of the most comprehensive reports about the Japan Patient Support Programs (PSP) Market, and offers unmatched value, accuracy, and expert insights

Report Scope Report Attribute Details Number of Pages 70-80 Base Year for Estimation 2022 Forecast Period 2023-2030 Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends, Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape, Reimbursement Scenario Report Coverage Quantitative Units Revenue in USD Million/Billion (Mn/Bn) Research Approach Secondary Research (60%), Primary Research (40%) Click on the icon to know the detailed methodology 3 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

Table of Content CONTENT PG. NO. 12-25 1. Patient Support Programs (PSP) Overview 1.1. Overview 1.2. Japan Overview 1.3. Economic Overview: Japan 1.4. Patient Support Programs (PSP) Market in Japan 1.5. Healthcare Services Market in Japan 1.6. Healthcare Scenario in Japan 1.7. Health Insurance Coverage: Japan 1.8. Budget of the Government for Public Insurance 1.9. Mergers and Acquisitions 26-32 2. Market Size and Forecasting 2.1 Market size and forecasts (Excel and Methodology) 4 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

Table of Content CONTENT PG. NO. 2.2. Market Segmentation 2.2.1. Functionality outlooks 2.2.2. Therapeutic area outlook 2.2.3. Application outlook 2.2.4. End-user 33-37 3. Market Dynamics 3.1. Market Growth Drivers 3.1.1. Japan Patient Support Programs (PSP) Market Driver 1 3.1.2. Japan Patient Support Programs (PSP) Market Driver 2 3.1.3. Japan Patient Support Programs (PSP) Market Driver 3 3.2. Market Restraints 3.2.1. Japan Patient Support Programs (PSP) Market Restraint 1 3.2.2. Japan Patient Support Programs (PSP) Market Restraint 2 5 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

Table of Content CONTENT PG. NO. 3.2.3. Japan Patient Support Programs (PSP) Market Restraint 3 38-48 4. Competitive Landscape 4.1. Major Market Share 4.2. Key Company Profile 4.2.1. Takeda Pharmaceutical Company 4.2.1.1. Overview 4.2.1.2. Product Applications & Services 4.2.1.3. Recent Developments 4.2.1.4. Partnerships Ecosystem 4.2.1.5. Financials (Based on Availability) 4.2.2. Astellas Pharma 4.2.2.1. Overview 6 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

Table of Content CONTENT PG. NO. 4.2.2.2. Product Applications & Services 4.2.2.3. Recent Developments 4.2.2.4. Partnerships Ecosystem 4.2.2.5. Financials (Based on Availability) 4.2.3. Daiichi Sankyo 4.2.3.1. Overview 4.2.3.2. Product Applications & Services 4.2.3.3. Recent Developments 4.2.3.4. Partnerships Ecosystem 4.2.3.5. Financials (Based on Availability) 4.2.4. Eisai 4.2.4.1. Overview 7 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

Table of Content CONTENT PG. NO. 4.2.4.2. Product Applications & Services 4.2.4.3. Recent Developments 4.2.4.4. Partnerships Ecosystem 4.2.4.5. Financials (Based on Availability) 4.2.5. Otsuka Pharmaceutical 4.2.5.1. Overview 4.2.5.2. Product Applications & Services 4.2.5.3. Recent Developments 4.2.5.4. Partnerships Ecosystem 4.2.5.5. Financials (Based on Availability) 4.2.6. Eli Lilly Japan K.K. 4.2.6.1. Overview 8 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

Table of Content CONTENT PG. NO. 4.2.6.2. Product Applications & Services 4.2.6.3. Recent Developments 4.2.6.4. Partnerships Ecosystem 4.2.6.5. Financials (Based on Availability) 4.2.7. Sanofi 4.2.7.1. Overview 4.2.7.2. Product Applications & Services 4.2.7.3. Recent Developments 4.2.7.4. Partnerships Ecosystem 4.2.7.5. Financials (Based on Availability) 4.2.8. Pfizer Japan 4.2.8.1. Overview 9 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

Table of Content CONTENT PG. NO. 4.2.8.2. Product Applications & Services 4.2.8.3. Recent Developments 4.2.8.4. Partnerships Ecosystem 4.2.8.5. Financials (Based on Availability) 4.2.9. AbbVie 4.2.9.1. Overview 4.2.9.2. Product Applications & Services 4.2.9.3. Recent Developments 4.2.9.4. Partnerships Ecosystem 4.2.9.5. Financials (Based on Availability) 4.2.10. Cancer Support Community Japan 4.2.10.1. Overview 10 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

Table of Content CONTENT PG. NO. 4.2.10.2. Product Applications & Services 4.2.10.3. Recent Developments 4.2.10.4. Partnerships Ecosystem 4.2.10.5. Financials (Based on Availability) 49-56 5. Reimbursement Scenario 5.1. Reimbursement Regulation 5.2. Reimbursement Process for Diagnosis 5.3. Reimbursement Process for Treatment 5.4 Reimbursement Process – Medicare 5.5 Reimbursement Process - Medicaid 57-62 6. Methodology & Scope 11 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

Japan Patient Support Programs (PSP) Market Analysis 1. Patient Support Programs (PSP) Overview

1.1 Statistics at a Glance: Patient Support Programs (PSP) in the World Patient Support Programs (PSP) at Global level Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ 90% Was PSPs impact adherence after one year 32% Is the percentage increase in number of PSP in the US In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic ▪ $70.3 Bn Is the forecasted valuation of Global PSP market for year 2030 17.4% Is the CAGR of the Global PSP market for the period of 2023-2030 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Key reasons For the impact of PSP are unaffordability and non-adherence to the treatments 13 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

1.1 Statistics at a Glance: The Status of Patient Support Programs (PSP) in the World (continued) Europe ~Revenue to reach $xx Bn by 2027 North America ~ Market Size of $xx Bn Asia -Fastest CAGR of xx% Africa Egypt Market ~$xx Mn Market ~Market Size of $xx Bn Illustrative Illustrative 14 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

1.2 Japan Overview Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ 125.8 Mn Is the population of Japan, in 2022 5.15 Tn Is the Gross Domestic Product (GDP) in Japan in 2021 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 48.4 years Is the median age in Japan, in 2022 $5.5k per capita was the amount of national health expenditures in 2021 15 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

1.3 Economic Overview: Japan Population of Japan, (2020-2030) GDP of Japan, (2020-2030) XX XX XX XX 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F Population Split (2023) In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ By Gender By Age Group In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 0-14 15-24 25-54 Male 49% Female 51% Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 55-64 65+ Illustrative Illustrative 16 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

1.4 Statistics at a Glance: Patient Support Programs (PSP) in Japan Prevalence of Patient Support Programs (PSP) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Pharmaceutical Companies ▪ Healthcare Providers and Institutions ▪ Patient Advocacy Groups ▪ In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic in Japan ▪ Government Agencies ▪ Non-profit Organizations ▪ Are the main providers of Patient Support Programs in Japan In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Individualized Medication Counselling ▪ Call Center Support ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Patient Advocacy ▪ Are the services provided by Patient Support Programs in Japan 17 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

1.5 Healthcare Services in Japan Japan PSP Market Forecast, 2022-2030 (in $Bn) xx xx xx xx xx xx xx xx xx 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the overall Healthcare Services market in Japan, which includes the market size, current trends and other details related to the topic ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 18 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

1.6 Healthcare Scenario in Japan Cancer Drug Development Process: The process of developing a cancer drug is complex and involves many stages, from preclinical research to clinical trials to regulatory approval. Here is a simplified diagram of the cancer drug development process: Preclinical Research: Researchers identify potential drug candidates and test them in the lab Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating cancer Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and effectiveness Regulatory Approval: The drug is reviewed by regulatory agencies such as the FDA and approved for use in the US market o o o o o FDA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and effectiveness. Here are four of these approaches: Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need ▪ Fast Track A process designed to expedite the development and review of drugs which may demonstrate substantial improvement over available therapy Breakthrough Therapy ▪ These regulations allowed drugs for serious conditions that filled an unmet medical need to be approved based on a surrogate endpoint Accelerated Approval ▪ Priority Review A Priority Review designation means FDA’s goal is to take action on an application within 6 months ▪ Illustrative Illustrative 19 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

1.6 Healthcare Scenario: Patient Journey Presentation Diagnosis Treatment Follow up Confirmatory Diagnosis Complete blood count (evaluate number & quality of RBCs, Hb & WBCs) Prevention and management of crisis: • For VOC and Splenic Sequestration: HU, Endari, Adakveo, Oxbryta • For infections: Antibiotics, Vaccines • Long term follow-up is required for patients with SCD • Annual assessment: CBC and reticulocyte count, iron status, liver and renal function tests, urinalysis, LDH, vitamin D level and neurocognitive assessment • ESOD (End Stage Organ Damage) evaluation starting from age 7 • Yearly Transcranial Doppler test to determine risk of stroke Initial Diagnosis Imaging (confirm bone related changes or respiratory problems) A suspected diagnosis is usually made, based on physical examination and detailed patient and family history Prenatal screening/ Neonatal screening Bacterial cultures of blood, sputum, urine, stool (detect any infection) Prevention and management of complications: Genetic testing (detect the type of SCD) • Stroke: Chronic transfusions, HU Stakeholders PCP, pediatrician, neonatologist, endocrinologist, cardiologist, hematologist, orthopedist, psychologist and psychiatrist PCP, paediatrician, neonatologist, haematologist and genetic counsellor PCP, pediatrician, medical geneticist, cardiologist, hematologist, endocrinologist, psychologist and psychiatrist PCP, pediatrician, medical geneticist, hematologist, gynecologist and pathologist Depending on the organ complications, the treatment involves different specialists at different times Illustrative Illustrative 20 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

1.7 Health Insurance Coverage: Japan % of People by Type of Health Insurance Coverage (2021) Number of People By Health Insurance Coverage Coverage Type 2020 2021 Change % 8.3 Uninsured Total 327,521 328,074 91.7 With health insurance Any health plan 299,230 300,887 0.4 Any private plan 217,896 216,366 –0.6 66.0 Any private plan Employment-based 178,737 178,285 –0.2 54.3 Employment-based Direct-purchase 33,869 33,555 –0.1 10.2 Direct-purchase Marketplace coverage 10,924 11,389 0.1 3.5 Marketplace TRICARE 9,165 8,299 –0.3 2.5 TRICARE Any public plan 112,925 117,095 1.2 Medicare 58,541 60,226 0.5 35.7 Any public plan 18.4 Medicare Medicaid 58,778 61,940 0.9 18.9 Medicaid VA and CHAMPVA 2,967 3,151 0.1 1.0 VA and CHAMPVA Uninsured 28,291 27,187 –0.4 In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire calendar year More people had private health insurance (66%) than public coverage (35.7%) Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%), followed by Medicaid (18.9%), Medicare (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care (1%) ▪ ▪ ▪ Illustrative Illustrative 21 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

1.8 Budget of Japan Government for Public Insurance Proposed Budget By Category 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31 Outlays $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633 Medicare In Billions Of Dollars $458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926 Medicaid 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7% Medicare As % Of GDP 2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4% Medicaid National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP) ▪ Medicare spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE ▪ Medicaid spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE ▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE ▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE ▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% of total NHE ▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020 ▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020 ▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020 ▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7% ▪ Illustrative Illustrative 22 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

1.9 Mergers and Acquisitions RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend $16.7 112 110 107 107 89 82 $11.7 $10.5 $7.7 $6.8 $6.0 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 Buyer Composition: Strategic Vs Financial (2020) Buyer Type by Deal Size ($Mn) 39% 41% 41% 42% 58% 59% 59% 61% Strategic Buyers Financial Buyers $0- $25 $25-$50 $50-$100 $100+ 57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020 Illustrative Illustrative 23 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

1.9 Mergers and Acquisitions (continued) Latest Deals In Japan Amount / Duration Company Name Type Year Key Pointers Japan's Astellas Pharma declared it agreed to buy U.S. drugmaker Iveric Bio Inc The deal marks the fifth major overseas acquisition by Astellas, Japan's third biggest drugmaker by sales It is the second-largest cross-border acquisition for a Japanese drugmaker in the past five years ▪ ▪ Acquisition $5.9 Bn May 2023 ▪ Moderna to Buy Japanese Firm OriCiro in Its First-Ever Acquisition ▪ In its inaugural acquisition, Moderna will buy the Japanese biotechnology company OriCiro Genomics and obtain its suite of genetic engineering tools ▪ January 2023 Acquisition $85 Mn OriCiro focuses on cell-free synthesis and amplification of plasmid DNAs ▪ 24 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

1.9 Mergers and Acquisitions (continued) Latest Deals In Japan Amount / Duration Company Name Type Year Key Pointers Merger March 2023 Merger Jan 2023 Illustrative Illustrative 25 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

Japan Patient Support Programs (PSP) Market Analysis 2. Market Size and Forecasting

2.1 Market size and forecasts (Excel and Methodology) Click on the icon to know the methodology and assumption Japan PSP Market Forecast, 2022-2030 (in $Bn) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ XX XX In this section you will get an understanding of the overall Healthcare Insurance market in Malaysia, which includes the market size, current trends and other details related to the topic ▪ 2022 2023F 2024F 2025F 2026F 2025 2027F 2026 2028F 2027 2029F 2030F 2023 2024 2028 2029 2030 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Major Markets Patient (Mn) 2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12 Malaysia Patient Size (Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ % of US Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45% Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937 Malaysia Market Size (Bn $) 61 74 84 87 91 95 99 106 Illustrative Illustrative 27 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

2.2 Snapshot of Japan PSP Market Segmentation Functionality Outlooks Therapeutic Area Outlook Application Outlook End-user Population Health Management Communication Health & Wellness Payers Chronic Disease Management Outpatient Health Management Health Tracking & Insights Providers In-patient Health Management Billing & Payments Others Others Administrative Others Patient Education In this section you will get an understanding of the segmentations which will cover the Japan Patient Support Programs (PSP) Market ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 28 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

2.2.1 Market Segmentation: By Functionality Outlooks Communication market in Japan is a significant component of the overall cancer treatment market ▪ Japan Cancer Market Share, By Functionality Outlooks (2022) It has the maximum market share in Japan cancer market with approximately xx% ▪ Patient Education Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Administrative Communication In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Billing & Payments Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Health Tracking & Insights 29 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

2.2.2 Market Segmentation: By Therapeutic Area Outlook Health & wellness market in Japan is a significant component of the overall cancer market ▪ Japan Cancer Market Share, By Therapeutic Area Outlook (2022) It has the maximum market share in Japan cancer market with approximately xx% ▪ Others Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Health & Wellness In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Chronic Disease Management 30 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

2.2.2 Market Segmentation: By Application Outlook Population health management market in Japan is a significant component of the overall cancer market ▪ Japan Cancer Market Share, By Application Outlook (2022) It has the maximum market share in Japan cancer market with approximately xx% ▪ Others Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Population Health Management In-patient Health Management In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Outpatient Health Management 31 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

2.2.3 Market Segmentation: By End User Payers have the maximum market share in Japan cancer market with approximately xx% ▪ Japan Cancer Market Share, By End User (2022) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Others In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Payers Providers 32 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

Japan Patient Support Programs (PSP) Market Analysis 3. Market Dynamics

3.1 Market growth drivers 3.1.1 Patient engagement and patient support have always been a leading concern for healthcare providers Disease burden is increasing in Japan, with more than xx Mn new cancer cases expected to be diagnosed in 2023 ▪ Incidence of Cancer in Japan This is driving the demand for disease treatments and creating opportunities for growth in the PSP market ▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 2010 2022 2030 Illustrative Illustrative 34 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

3.1 Market growth drivers (continued) 3.1.2 1. Leverage digital technologies to enhance patient experience and medication compliance Top countries that are leveraging technology for PSP growth Japan has a long history of investing in cancer research and treatment, and as a result, has become a world leader in the field ▪ Norway IT has a robust healthcare infrastructure, including world- renowned research institutions, hospitals, and clinics, that are dedicated to cancer treatment and research ▪ Austria Denmark Belgium Spain One of the key factors that has allowed Japan to stay ahead in the field of cancer research and treatment is the high level of investment in cancer-related research ▪ Italy Netherlands Sweden Singapore Switzerland In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Israel Australia Canada Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ France United Kingdom China South Korea Germany Japan United States Illustrative Illustrative 35 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

3.1 Market growth drivers (continued) 3.1.3 4. Integrate PSP insights into your value proposition to drive brand differentiation Fundings from government and other organizations Japan government provides significant support and funding for cancer research and treatment, which is driving innovation and growth in the cancer market ▪ Source Year Fund ($) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ National Cancer Institute (NCI) 2021 $ 6.4 Bn In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Centers for Disease Control and Prevention (CDC) 2021 $ 501 Mn Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ American Cancer Society (ACS) 2020 $ 150 Mn Susan G. Komen 2020 $ 98 Mn Illustrative Illustrative 36 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

3.2 Market restraints 3.2.1 In 2020, the average cost of a new cancer drug was over $150,000 per year 3.2.2 Average cost of developing a new cancer drug that is ultimately approved by the FDA is over $2.6 Bn 3.2.3 Demand for cancer care is expected to increase by 42% by 2025, while the supply of oncologists is only expected to increase by 28% Cancer treatments can be very expensive and can lead to financial burden for patients and healthcare systems Cost of cancer treatment varies depending on the type of cancer, stage of cancer, and treatment options Some common cancer treatments, such as chemotherapy and radiation therapy, can cost tens of thousands of dollars Regulatory requirements for cancer treatments can be very stringent, which can slow down the approval process and limit access to new treatments Regulatory bodies, such as Japan Food and Drug Administration (FDA), require extensive clinical trials and safety data before approving new cancer treatments This can be a lengthy and costly process, which can delay the availability of new treatments for patients There is a shortage of oncologists in Japan, which can limit access to cancer treatments and create barriers to growth in the cancer market Oncologists are physicians who specialize in the diagnosis and treatment of cancer With the aging population and the increasing incidence of cancer, there is a growing demand for oncologists However, the supply of oncologists is not keeping pace with the demand ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ Our analysis will thoroughly investigate the key restraints that may significantly impact business operations and growth. Illustrative Illustrative 37 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

Japan Patient Support Programs (PSP) Market Analysis 4. Competitive Landscape

4.1 Major Market Share Japan PSP market is a highly competitive space, with many companies developing and marketing cancer treatments ▪ Revenue of Major players in Japan PSP Market ($ Mn) Some of the top companies in Japan cancer market based on revenue and market share include ▪ Other Takeda Pharmaceutical Company is a Swiss multinational healthcare company that develops and markets cancer treatments, including targeted therapies and immunotherapies ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ XX Illustrative Illustrative 39 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

4.2 Key Company Profile Key Note: Takeda Pharmaceutical Company 1 Here is the list of top 10 companies which will cover in the final report ▪ 2 Astellas Pharma Each company will have slides for ▪ 3 Overview Key details Offerings Name of products Recent activities/ Press Coverage Distribution and Vendor Partners Mergers, Acquisitions and Collaboration Financials If there are specific companies that you would like to be included in the report, please let us know via email In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Daiichi Sankyo o o 4 Eisai o o 5 Otsuka Pharmaceutical o 6 o o Eli Lilly Japan K.K. 7 Sanofi o 8 Pfizer Japan ▪ 9 AbbVie ▪ Cancer Support Community Japan 10 40 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

4.2.1 Takeda Pharmaceutical Company Focus Areas of Takeda Pharmaceutical Company Founded in: 1781 ▪ It is a research-based pharmaceutical company which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of pharmaceutical drugs ▪ Takeda has facilities in Japan, Argentina, Brazil, Mexico, the US, Denmark, Norway, Europe, Poland, Russia, Spain, Switzerland, China, India, and Canada among others ▪ Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies ➢ Rare Diseases HQ: Tokyo, Japan ➢ Gastrointestinal Type: Public ➢ Oncology Revenue: $31.8 Bn ➢ Neuroscience ➢ Vaccines Website: www.takeda.com ➢ Plasma-derived Therapies Services offered Recent Activity / Press Coverage Indications Initiatives aimed at raising awareness of IBD to be close to and contribute to IBD patients Oncology Patient Advocacy and Engagement (PA&E) Disease Edcuation Joint Research Results for Analysis and Visualization of the Patient Journey of Ovarian Cancer Patients Presented at ISPOR 2023 International Society for Pharmacoeconomic and Outcomes Research Takeda Oncology Here2Assist Astellas Pharma, Eisai, Daiichi Sankyo, and Takeda Collaborate in the Pharmaceutical Packaging Field to Reduce Environmental Impact 41 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

4.2.1 Takeda Pharmaceutical Company (continued) Partnerships Ecosystem Major Investments Licensing Agreements ▪ Takeda to obtain exclusive worldwide rights to develop, manufacture and commercialize Antibody Drug Conjugates (ADC) using a panel of selected antibodies developed by Innate ▪ Oshi Health is a completely redesigned gastrointestinal care experience ▪ Takeda will be responsible for the future development, manufacture and commercialization of any potential products developed using the licensed antibodies. ▪ Oshi Health Secures $23 Mn Series A to Scale Transformational Virtual Specialty Care from venture capitalists including Takeda ▪ Flare Capital Partners, Bessemer Venture Partners, Frist Cressey Ventures, CVS Health Ventures and notable angel investors back Oshi Health’s novel, integrated care model for gastrointestinal health ▪ F-star Therapeutics Announces a License Agreement with Takeda ▪ Under the agreement, F-star grants Takeda a worldwide, exclusive royalty- bearing license for bispecific antibody against an immuno-oncology target using F-star’s proprietary Fcab™ and mAb2 ™ platforms 42 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

4.2.1 Takeda Pharmaceutical Company (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers Takeda Pharmaceutical announced more than $650,000 in grant funding was awarded to 18 organizations through the Improving Health Equity in Cancer: A Community Grant Program The grants were provided to patient advocacy organizations that are helping to address the needs of medically underserved people with cancer through community-based initiatives ▪ March, 2023 Grant $ 650,000 ▪ Takeda has entered into an exclusive licensing agreement with HUTCHMED (China) Limited and its subsidiary HUTCHMED Limited, for the further development and commercialization of fruquintinib outside of mainland China, Hong Kong and Macau ▪ Acquisition of Licensing Agreement January 2023 - 43 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

4.2.1 Takeda Pharmaceutical Company (continued) Revenues ($Bn), 2020-2030 According to Takeda Pharmaceutical Company's 2022 financial report, the company had revenue of $31.8 Bn in 2022 ▪ The net profit margin of Takeda Pharmaceutical has increased by 22% from 2022 xx ▪ xx xx Revenue generated by Takeda Pharmaceutical Company in 2022 reflects the company's continued growth and success in the healthcare industry ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F Breakdown of Net Revenue by Segment, 2022 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 1 2 3 4 Illustrative Illustrative 44 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

4.2.2 Company 2 Solutions offered by Company Founded in: HQ: Type: Revenue: Website: Drugs for Cancer Recent Activity / Press Coverage Drugs Indications Illustrative Illustrative 45 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

4.2.2 Company 2 (continued) Partnerships Ecosystem Major Distribution Partners Major Vendor Partners Illustrative Illustrative 46 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

4.2.2 Company 2 (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers Illustrative Illustrative 47 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

4.2.2 Company 2 (continued) Revenues ($Bn), 2020-2030 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ xx xx xx In this section you will the understating of financial overview of the company, which includes revenue forecasting, segment revenue and other key details as per availability ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Breakdown of Net Revenue by Segment, 2022 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 1 2 3 4 Illustrative Illustrative 48 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

Japan Patient Support Programs (PSP) Market Analysis 5. Reimbursement Scenario

5.1 Reimbursement Regulation in Japan Medicare and Medicaid together provide health insurance coverage for more than 4 in 10 Americans The reimbursement scenario in the US cancer market is complex and can vary depending on the specific treatment, setting of care, and insurance coverage. Here are some key points to consider: Medicare: o ▪ Medicare is a federal health insurance program for people aged 65 and older, as well as people with certain disabilities or health conditions Medicare covers many cancer treatments, including chemotherapy, radiation therapy, and some immunotherapies However, coverage can be subject to strict guidelines and restrictions, such as the requirement for prior authorization Medicaid: o Medicaid is a joint federal-state program that provides health insurance for people with low incomes o Medicaid coverage for cancer treatments can vary by state, and may be subject to limits on the amount and type of treatment covered Private Insurance: o Private insurance coverage for cancer treatments can also vary widely depending on the insurer and the specific policy o Some policies may have high out-of-pocket costs, such as deductibles and co-pays, while others may have more comprehensive coverage Other Public 1% o Other Private 3% Uninsured 9% Medicare 17% o ▪ Medicaid and CHIP 21% ▪ Employer-Sponsored 49% Health Insurance Coverage, 2022 Illustrative Illustrative 50 A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential

Japan Patient Support Programs (PSP) Market Analysis Sample Report